Last reviewed · How we verify
Prometrium
At a glance
| Generic name | Prometrium |
|---|---|
| Also known as | Progesterone, progesterone capsules |
| Sponsor | Mount Sinai Hospital, Canada |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy of Micronized Natural Progesterone vs GnRH Antagonist in the Prevention of LH Peak During Ovarian Stimulation. (PHASE4)
- Comparison of Oral Dydrogesterone and Vaginal Progesterone in Menopausal Hormone Therapy (NA)
- Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency (PHASE3)
- Luteal Support in Artificial Vitrified/Warmed Cycles With Low Progesterone (PHASE3)
- INTEnsity of ovariaN Stimulation and Embryo Quality (PHASE4)
- Artificial Cycle With or Without GnRH Agonist Pre-treatment for Frozen Embryo Transfer in Adenomyosis Patients (NA)
- First in Human Safety and Ease of Use Assessment of 400mg Progesterone Callavid in Women With Luteal Phase Insufficiency (PHASE1)
- Impact Of FET Preparation Protocol On Endometrial Peristalsis: A Prospective Cohort Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prometrium CI brief — competitive landscape report
- Prometrium updates RSS · CI watch RSS
- Mount Sinai Hospital, Canada portfolio CI